March 21 (Reuters) – BioMarin Pharmaceutical Inc said preliminary data showed its experimental drug met the main goal of reducing blood phenylalanine in patients with a genetic disorder, in a…
The post BioMarin drug for genetic disorder succeeds in late-stage study appeared first on NASDAQ.